EFFECT OF ANTIEPILEPTIC DRUG ON THE SERUM FOLATE AND VITAMIN B12 LEVEL IN EPILEPTIC PATIENTS

Dissertation Submitted to

THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY

In partial fulfillment of the requirements

For the award of degree of

M.D. (Branch-XIII)

BIOCHEMISTRY

GOVERNMENT STANLEY MEDICAL COLLEGE & HOSPITAL

THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY,

CHENNAI, TAMILNADU

MAY 2019

CERTIFICATE

This is to certify that the dissertation titled, ***"EFFECT OF ANTIEPILEPTIC DRUG ON THE SERUM FOLATE AND VITAMIN B12 LEVEL IN EPILEPTIC PATIENTS"*** is a genuine work done by **Dr.S.KAVITHA** for the partial fulfillment of the requirements for M.D (Biochemistry) Branch XIII Examination of The Tamil Nadu Dr. M.G.R. Medical University to be held in May 2019, during the academic period 2016-2019.

Dr. S. PONNAMBALA NAMASIVAYAM
MD., D.A., D.N.B.,
Dean
Stanley Medical College &Hospital,
Chennai-1

Dr. R. SHANTHI
M.D., D.C.P.,
Professor & HOD
Department of Biochemistry
Stanley Medical College &
Hospital,
Chennai-1

CERTIFICATE BY GUIDE

This is to certify that the dissertation on **"*EFFECT OF ANTIEPILEPTIC DRUG ON THE SERUM FOLATE AND VITAMIN B12 LEVEL IN EPILEPTIC PATIENTS*"** is a record of research work done by **Dr.S.KAVITHA** in partial fulfillment for M.D (BIOCHEMISTRY) Examination of The Tamil Nadu Dr. M.G.R. Medical University to be held in May 2019. The period of study is from January 2018 to June 2018.

Dr.R.SHANTHI M.D., D.C.P.,

Department of Biochemistry,

Government Stanley Medical College,

Chennai - 600 001

DECLARATION

I, **Dr.S.KAVITHA**, solemnly declare that the dissertation titled ***"EFFECT OF ANTIEPILEPTIC DRUG ON THE SERUM FOLATE AND VITAMIN B12 LEVEL IN EPILEPTIC PATIENTS"*** is a bonafide work done by me during the period of January 2018 to June 2018 at Government Stanley Medical College and Hospital, Chennai under the expert guidance of **Dr.R.SHANTHI M.D., D.C.P.**, Department Of Biochemistry, Government Stanley Medical College and Hospital, Chennai.

This thesis is submitted to The Tamil Nadu Dr. M.G.R. Medical University in partial fulfillment of the rules and regulations for the M.D. degree examinations in Biochemistry to be held in May 2019.

Chennai-1

Date: **Dr. S. KAVITHA**

GOVERNMENT STANLEY MEDICAL COLLEGE& HOSPITAL,CHENNAI -01

INSTITUTIONAL ETHICS COMMITTEE

Title of the Work : "EFFECT OF ANTIEPILEPTIC DRUG ON THE SERUM FOLATE AND VITAMIN B12 LEVEL IN EPILEPTIC PATIENTS".

Principal Investigator : DR. S.KAVITHA,

Designation : MD BIOCHEMISTRY,

Department : Department of BIOCHEMISTRY,
Govt. Stanley Medical College.

The request for an approval from the Institutional Ethical Committee (IEC) was considered on the IEC meeting held on 21.12.2017 at the Council Hall, Stanley Medical College, Chennai-1 at 10am.

The members of the Committee, the secretary and the Chairman are pleased to approve the proposed work mentioned above, submitted by the principal investigator.

The Principal investigator and their team are directed to adhere to the guidelines given below:

1. You should inform the IEC in case of changes in study procedure, site investigator investigation or guide or any other changes.
2. You should not deviate from the area of the work for which you applied for ethical clearance.
3. You should inform the IEC immediately, in case of any adverse events or serious adverse reaction.
4. You should abide to the rules and regulation of the institution(s).
5. You should complete the work within the specified period and if any extension of time is required, you should apply for permission again and do the work.
6. You should submit the summary of the work to the ethical committee on completion of the work.

MEMBER SECRETARY,
IEC, SMC, CHENNAI


URKUND
kavitha (kavi.stanly2016)
Document DrKavitha New Master Copy.doc (D42287890)
Submitted 2018-10-08 22:56 (+05:0-30)
Submitted by kavitha (kavi.stanly2016@gmail.com)
Receiver kavi.stanly2016.mgrmu@analysis.urkund.com
3% of this approx. 20 pages long document consists of text present in 2 sources.
Sources
Highlights
Rank
Path/Filename
Dessertation sample.docx
http://shodhganga.inflibnet.ac.in/bitstream/10603/6742/9/09_chapter%203.pdf
Plagiarism.docx
Alternative sources
Plagiarism.docx
Plagiarism.docx
1 Warnings
Reset
Export
Share
94%
#1
Active
INTRODUCTION
Epilepsy is a chronic neurological disorder caused by transient cerebral dysfunction due to disordered electrical activity of human brain. It is a common neurological disease with world-wide prevalence of 7.0 % 1. According to various studies the prevalence rate of epilepsy in India is at 5.59 / 1000 population with no statistical difference rate between men and women 2.
The main stay of treatment for epilepsy is medical treatment. Despite the use of newer antiepileptic drugs like TOPIRAMATE, LAMOTRIGINE in the treatment of epilepsy, phenytoin still remains drug of choice. As phenytoin has broad spectrum of activity and tolerability it is commonly used in epileptic patients 3.
Even though phenytoin drug has many advantages, its long term use causes deficiency of Vitamin B12 and Folic acid. Over 50% of patients on long term phenytoin therapy demonstrate low level of serum vitamin B12 and Folic acid. Previous studies had reported that increasing duration of phenytoin drug treatment alters the bio availability and metabolism of vitamin B12 and Folic acid 4. The manifestation of the two deficiency states includes megaloblastic anaemia, cognitive impairment and depression.
A survey conducted at neurology department, Stanley Medical College Hospital showed that the number of epileptic patients on phenytoin monotherapy has increased significantly over the period of time.
Urkund's archive: / Dessertation sample.docx
94%
The contents of the source document cannot be displayed!
Possible reasons:
1. The document is stored in the URKUND Partner section and is listed as inaccessible. If you do not own this book already, you need to purchase it from the vendor.
2. The document has been exempted as a viewable source in the URKUND Archive by the author.

CERTIFICATE-II

This is to certify that this dissertation work titled **"EFFECT OF ANTIEPILEPTIC DRUG ON THE SERUM FOLATE AND VITAMIN B12 LEVEL IN EPILEPTIC PATIENTS"** of the candidate **Dr. S.KAVITHA** with registration number **201623051** for the award of **M.D. BIOCHEMISTRY** in the branch of **XIII**. I personally verified the urkund.com website for the purpose of plagiarism check. I found that the uploaded thesis file contains from introduction to conclusion pages and result shows **3%** percentage of plagiarism in the dissertation.

Guide & Supervisor sign with Seal

ACKNOWLEDGEMENTS

First and foremost, I thank the Almighty. Without Him nothing would have been possible. With God's Grace, everything is possible.

I wish to express my sincere thanks to **Dr.S.PONNAMBALA NAMASIVAYAM, MD., D.A., D.N.B., Dean,** Government Stanley Medical College and Hospital for permitting me to utilize the facilities of the hospital for the conduct of the study.

My heartfelt gratitude to **Dr. R. SHANTHI M.D., D.C.P., Professor,** for her constant encouragement, immense support, valuable and constructive suggestions, corrective comments and expert supervision.

My heartfelt gratitude to **Dr.M.P.SARAVANAN, M.D., Professor,** for his motivation, valuable suggestions, expert guidance and immense support.

I would like to express my sincere gratitude to **Dr.M.VIJAYALAKSHMI, M.D., Associate Professor,** for her extra ordinary support, innovative ideas, valuable suggestions and corrective comments right from my presentation in ethical committee.

I would also like to thank **DR.V.G.KARPAGHAVALLI, M.D., D.G.O., Associate Professor,** for her valuable suggestion and support in carrying my dissertation work.

I thank **Dr. S. ARUNAN, M.D., D.M., Professor and Head of the Department of Neurology**, for permitting me to conduct the study and for his expert supervision during my dissertation period.

I thank **Dr. V. ARUNA LATHA, M.D., Professor and Head of the Department of Pathology** for permitting me to conduct the study in clinical pathology laboratory.

I wish to thank all **Assistant Professors** especially for their aid, keen interest, encouragement, and corrective comments during the research period, and I express my sincere thanks to my postgraduate colleagues for their enthusiasm and involvement for completing this study.

I thank all the staffs and technicians, Government Stanley Medical College and Hospital for their cooperation and assistance.

I am indebted to my parents for their care and moral support during the period of my study and I thank my husband **Dr. M. Kathiravan, ME., Ph.D.,** for his patience and moral support during the period of my study, without which it would be difficult for me to complete this study.

Last but definitely not the least; I would like to thank all the patients who cooperated with me throughout my work.

INDEX

S. No	Contents	Page. No
1.	Introduction	1
2.	Review of Literature	5
3.	Aim and Objectives	32
4.	Materials and Methods	34
5.	Statistical Analysis & Results	53
6.	Discussion	78
7.	Summary	83
8.	Conclusion	85
	ANNEXURES	
	i. Bibliography	
	ii. Master chart	
	iii. Proforma	
	iv. Consent form	

ABBREVIATIONS

1.	AED	-	Antiepileptic Drug
2.	CBL	-	Cobalamin
3.	DHFR	-	Dihydro Folate Reductase
4.	EEG	-	Electro Encephalogram
5.	ECL	-	Electro Chemiluminescence
6.	FA	-	Fatty Acid
7.	GABA	-	Gamma Amino Butyric Acid
8.	HC	-	Homo Cysteine
9.	ILAE	-	International League Against Epilepsy
10.	IF	-	Intrinsic Factor
11.	MTHF	-	Methyl Tetra Hydro Folate
12.	MCV	-	Mean Corpuscular Volume
13.	MCH	-	Mean Corpuscular Haemoglobin
14.	MCHC	-	Mean Corpuscular Haemoglobin Concentration
15.	MMA	-	Methyl Malonic Acid
16.	SAM	-	S adenosyl Methionine
17.	TPA	-	Tripropyl Amine
18.	THF	-	Tetra Hydro Folate

INTRODUCTION

INTRODUCTION

Epilepsy is a chronic neurological disorder caused by transient cerebral dysfunction due to disordered electrical activity of human brain. It is a common neurological disease with world-wide prevalence of 7.0 % [1]. According to various studies the prevalence rate of epilepsy in India is at 5.59 / 1000 population with no statistical difference rate between men and women [2].

The main stay of treatment for epilepsy is medical treatment. Despite the use of newer antiepileptic drugs like Topiramate, Lamotrigine etc, in the treatment of epilepsy, phenytoin still remains drug of choice. As phenytoin has broad spectrum of activity and tolerability it is commonly used in epileptic patients [3].

Even though phenytoin drug has many advantages, its long term use causes deficiency of Vitamin B12 and Folic acid. Over 50% of patients on long term phenytoin therapy demonstrate low level of serum vitamin B12 and Folic acid. Previous studies had reported that increasing duration of phenytoin drug treatment alters the bio availability and metabolism of vitamin B12 and Folic acid [4]. The manifestation of the two deficiency states includes megaloblastic anaemia, cognitive impairment and depression.

A survey conducted at neurology department, Stanley Medical College Hospital showed that the number of epileptic patients on phenytoin monotherapy has increased significantly over the period of time.

Vitamin B12 and Folic acid deficiency found associated with long term phenytoin monotherapy should be treated to improve the quality and longevity of patient's life.

This study was undertaken to evaluate the level of Vitamin B12 and Folic acid in epileptic patients on phenytoin monotherapy, so that anemia due to Vitamin B12 and Folic Acid deficiency can be prevented by supplementing these vitamins to the patients.

REVIEW OF LITERATURE

REVIEW OF LITERATURE

Epilepsy is one of the diseases that has been identified and recorded since the beginning of charted history. It was thought to be spiritual possession state by many including Mesopotamians (2000 BC); Babylonians, Punarvasa atreya (900 BC), and Charaka (400 BC) [5]. Ancient Greeks believed epilepsy to be connected to Intellect and ability and they thought the people affected had superhuman abilities like Hercules and called it the sacred disease. In the fifth century BC HIPPOCRATES was the first person to believe that it was a disease of the Brain and called it as the "great disease" thus the origin of the modern term Grand Mal. The first anti epileptic medication "bromide" was introduced in mid 1800's. Phenobarbitone was developed in 1912 and Phenytoin in 1938.

DEFINITION

Epilepsy is a disorder characterized by paroxysmal cerebral dysrhythmia, manifesting as brief episodes of loss or disturbance of consciousness, with or without characteristic body movements. Epilepsy is the second most common chronic neurological condition. Epileptic seizures result from abnormal, excessive or hyper synchronous neuronal activity in the brain [6].

EPIDEMIOLOGY

Epilepsy is the second most common chronic neurological condition seen by neurologists. The common causes are stress, trauma, CNS infections, brain tumors, and illicit drug use and alcohol withdrawal and cerebrovascular disease[7].

It is estimated that there are 55, 00,000 people with epilepsy in India, 20, 00,000 in USA and 3, 00,000 in UK. Three to five per cent of the populations have a seizure some time in their life and half to one per cent of the population have active epilepsy [7]. There are no incidence studies of epilepsy from India. Studies from developed countries and a few developing countries suggest that the incidence of epilepsy is higher in developing countries more than 100/100,000 population [8].

TYPES

The epileptic seizures are of various types and are most commonly defined and grouped according to the scheme proposed by the International League against Epilepsy (ILAE) [9].



FIG 1: THE NEW CLASSIFICATION OF SEIZURES TYPES PROPOSED BY INTERNATIONAL LEAGUE AGAINST EPILEPSY (ILAE)

This classification is based on observation (clinical and EEG) rather than the underlying pathophysiology or anatomy [10].

I. **Partial seizures (Older term: focal seizures)**

A. Simple partial seizures - consciousness is not impaired

- With motor signs
- With sensory symptoms
- With autonomic symptoms or signs
- With psychic symptoms

B. Complex partial seizures - consciousness is impaired (Older terms: temporal lobe or psychomotor seizures)

- Simple partial onset, followed by impairment of consciousness
- With impairment of consciousness at onset

C. Partial seizures evolving to secondarily generalized seizures

- Simple partial seizures evolving to generalized seizures
- Complex partial seizures evolving to generalized seizures
- Simple partial seizures evolving to complex partial seizures evolving to generalized seizures

II. Generalized seizures

A. Absence seizures (Older term: petit mal)

- Typical absence seizures
- Atypical absence seizures

B. Myoclonic seizures

C. Clonic seizures

D. Tonic seizures

E. Tonic–clonic seizures (Older term: grand mal)

F. Atonic seizures

ETIOLOGY

In infants and children, the common causes of seizures are perinatal injuries, hypoxia, congenital malformations, metabolic disturbances, developmental disorders, and acute CNS infections. Among young adults, the predisposing factors for seizures are head injury, CNS infection, alcohol withdrawal and arteriovenous malformations and brain tumour. In case of geriatrics,the causes for seizures are metabolic disorders, cerebrovascular disorders and brain tumors . Seizures may also be idiopathic.

Neonates <1 month	Infants < 12 years	Adolescents 12-18 years	Young adult 18-35 years	Older >35 years
Perinatal hypoxia and ischemia	Febrile seizures	Trauma	Trauma	Drugs and alcohol
ICH	CNS infection	CNS infection	CNS infection	Trauma
Ca^{++} , Glucose Bilirubin	Trauma	AVM	Brain tumor	Tumor
Water intoxication	Developmental disorder	Infection	AVM	CVD
Inborn error of metabolism	Inborn error of metabolism	Congenital defect	Drugs and alcohol	Degenerative
Trauma		Tumors		CNS infection

PATHOPHYSIOLOGY

The onset of seizures occurs due to prolonged depolarization of a small group of abnormal neurons associated with the rapid firing of repeated action potentials. These neurons recruit adjacent neurons by which they are also connected in the process. When the electrical discharges of a large number of cells become abnormally

linked together, it creates a storm of electrical activity in the brain, resulting in a clinical seizure, which may spread to adjacent areas of the brain.

Seizures result from an imbalance between excitatory and inhibitory processes in the brain. Proposed mechanisms for the generation and spread of seizure activity within the brain are abnormalities in the membrane properties of neurons, changes in the ionic microenvironment surrounding the neuron, decreased inhibitory neurotransmission primarily by gamma amino butyric acid (GABA) or enhanced excitatory neurotransmission mediated by glutamate.



Fig 2: Mechanism of Action of Phenytoin

SIGNS AND SYMPTOMS

The signs and symptoms of vary depending on the type of seizures [11]. Seizures may cause involuntary changes in body movement or function, sensation, awareness, or behavior. Seizures are often associated with a sudden and involuntary contraction of a group of muscles and loss of consciousness.



FIG 3: SIGN AND SYMPTOMS

DIAGNOSIS OF EPILEPSY

For diagnosis of epilepsy, Electro Encephalo Gram (EEG), and imaging tests are performed. Specific blood investigations are also done to detect metabolic causes [12].

- **Electro Encephalo Gram**

An EEG measures the electrical activity in the brain and helps to uncover many abnormalities. 24-hour EEG is necessary in some cases to determine the precise frequency and nature of any unusual electrical activity in the brain. An abnormal EEG does not necessarily confirm the disease and a normal EEG does not rule out the possibility of epilepsy.

- ***Imaging tests***

Imaging techniques like Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Single Positron Emission Computed Tomography (SPECT) or cerebral angiogram are useful in identifying structural abnormalities within the brain such as tumours and lesions that provoke seizures.

- ***Blood tests***

Routine blood tests like sodium, calcium, glucose, liver and kidney function are performed. These tests help to identify other causes of seizures, such as hyperglycemia, hypoglycemia, or electrolyte imbalances. Specific blood tests help in the determination of etiological factors of seizures like infection, poisoning and alcohol or other drug abuse.

PHARMACOLOGICAL TREATMENT

- **First generation antiepileptic drugs**

The modern treatment of epilepsy began with potassium bromide. The first mention of bromide in the English literature can be found on pages 327–328 in the Lancet of 23rd May, 1857 during the discussion of a paper presented at the Royal Medical and Chirurgical Society by Dr Edward Sieveking [13]. Introduction of bromide was followed by phenobarbital, phenytoin, primidone, ethosuximide, benzodiazepine, carbamazepine and sodium valproate which were introduced to the market and considered as older AEDs. The details about the antiepileptic drug development are given in Fig. 4.



FIG 4: HISTORY OF ANTIEPILEPTIC DRUGS

SECOND GENERATION ANTIEPILEPTIC DRUGS

Second generation‘ antiepileptic drugs (AEDs) which have entered the marketplace since 1990 include gabapentin (GBP), felbamate (FBM), oxcarbazepine (OXC), lamotrigine (LTG), levetiracetam (LEV), tiagabine (TGB), topiramate (TPM), vigabatrin, and zonisamide (ZNS).[14] These new AEDs are currently taken by approximately 16% of patients with epilepsy receiving antiepileptic drug treatment.[15]

TREATMENT OF EPILEPSY

Therapy for a patient with a seizure disorder always includes treatment of underlying conditions which cause seizures, avoidance of precipitating factors and suppression of recurrent seizures by prophylactic therapy with AEDs or surgery. phenytoin and carbamazepine act by modulation of voltage dependent ionic channels. Benzodiazepines, phenobarbitone and tiagabine act by enhancing the activity of

GABA, the major inhibitory neurotransmitter in the brain. Felbamate and Lamotrigine act by suppressing the excitatory neurotransmission

PHENYTOIN

Phenytoin (diphenylhydantoin) is one of the most widely used antiepileptic drugs recommended against generalized or partial seizures. It is used as a first line drug for generalized tonic-clonic, simple and complex partial seizures, second line drug for atonic and atypical absences. It is not effective in typical generalized absence and myoclonic seizures. phenytoin was first synthesized by German chemist Heinrich Biltz in 1908. Phenytoin suppresses the abnormal brain activity seen in seizure by reducing the electrical conductance among brain cells via stabilizing the inactive state of voltage-gated sodium channels. The drug limits the spread of seizure activity without causing CNS depression. It is occasionally used in status epilepticus and trigeminal neuralgia and as a second drug of choice in cardiac arrhythmias induced by digitalis.



IUPAC Name: 5, 5 -diphenylimidazolidine-2, 4-Dione [55]

FIG 5: STRUCTURE OF PHENYTOIN

MECHANISM OF ACTION OF PHENYTOIN

Phenytoin blocks voltage sensitive neuronal sodium channels in neuronal tissue causing prolongation of the rate of recovery and reduces the frequency of sustained repetitive firing of action potentials. It blocks post tetanic potentiation, limits development of maximal seizure activity and reduces the spread of seizures.



FIG 6: ACTION OF PHENYTOIN

- **Pharmacokinetics of Phenytoin**

Absorption of phenytoin by oral route is slow, mainly because of its poor aqueous solubility. The peak serum levels are attained at about 2 to 8 hr, inter individual differences were observed during long-term therapy. 80-90% of drug is bound to plasma proteins, its oral bioavailability is approximately 95% and the volume of distribution is 0.5 - 0.8 L/Kg. It is excreted through kidneys and its elimination half life is 7-42 hrs. Phenytoin is metabolized principally in the hepatic endoplasmic reticulum mainly by the enzyme cytochrome P450 (CYP).



FIG 7: Pharmacokinetics of Phenytoin

- **Drug interactions of Phenytoin**

Interactions between phenytoin, phenobarbitone and carbamazepine are well established. Chloramphenicol, isoniazid, cimetidine, dicoumarol and warfarin inhibit phenytoin metabolism and precipitate its toxicity. Phenytoin induces microsomal enzymes and increases the degradation of steroids, digoxin, doxycycline, theophylline etc. Sucralfate binds with phenytoin in the gastrointestinal tract and decreases its absorption.

USES

- Generalized tonic-clonic, simple and complex partial seizures.
- It is ineffective in absence seizures
- Status epilepticus: occasionally used by slow i.v injection.
- Trigeminal neuralgia – second choice drug to carbamazapine

ADVERSE EFFECTS OF PHENYTOIN

Serum levels of phenytoin within a range of 10 to 20 μg/ml offer satisfactory seizure control in most of the patients [16, 17, 18, 19] and the toxic signs are rare below 15μg/ml.

- ***Neurotoxicity*** **–** Nystagmus, Ataxia, Cognitive Dysfunction
- ***Teratogenicity*** **–** Foetal Hydantoin Syndrome
- ***Gingival Toxicity*** **–** Gingival Hyperplasia
- ***Hepatotoxicity***
- ***Osteomalacia***
- ***Infertility***
- ***Visualtoxicity***
- ***Haematotoxicity***

Phenytoin was observed to cause reduction in folic acid levels and induce megaloblastic anemia. Phenytoin also induces agranulocytosis, aplastic anemia, leukopenia, and thrombocytopenia. Phenytoin induced haematotoxicity was believed to be mediated via epoxide metabolites of phenytoin.

MECHANISM OF PHENYTOIN INDUCED TOXICITY

The toxicity associated with phenytoin, may be due to its bio-activation to reactive oxygen species [20]. Phenytoin is bio-activated by peroxidases such as prostaglandin H synthase to free radical intermediates that initiate the formation of ROS such as hydroxyl radicals [21], which in turn oxidize the lipids, proteins, carbohydrates and DNA [22]. This damage ultimately leads to cellular disruption, implicating a role for oxidative stress in phenytoin initiated toxicity [23].



FIG 8: MECHANISM OF PHENYTOIN TOXICITY

The mechanism for Vitamin B12 deficiency induced by phenytoin therapy is not yet precisely defined. Several studies had been done to explain the mechanism by which phenytoin alters the metabolism of folate [24, 25, 26]. However reports on phenytoin – Vitamin B12 interaction are scanty. Over 50 % of patients on long term phenytoin therapy demonstrate low serum level of folic acid and vitamin B12 [27].

FOLIC ACID

Folate is a general term related to a family of substances containing a pteridine ring joined to both *p*-aminobenzoic acid and glutamic acid [28]. Reduced forms of this molecule are called dihydrofolate and tetrahydrofolate.



FIG 9: STRUCTURE OF FOLIC ACID [56]

ABSORPTION TRANSPORT AND STORAGE

Most of the dietary folic acid found as polyglutamate with 3 to 7 glutamate residues and is not absorbed in the intestine. The enzyme folate conjugase present in duodenum and jejunum split the glutamate residues and only the mono glutamate form of folic acid is absorbed in the jejunum by means of passive transport. Once taken up by the enterocyte, the enzyme (DHFR) mediates the conversion of folic acid to Methyl tetra hydro Folate (MTHF). The folate then exits the enterocyte via the basolateral membrane and taken into the systemic circulation. In the systemic circulation 66% binds to albumin, 33% free and 1% binds to FP. It enters the cell by binding to RTF1 or RTF2. Inside the cell MTHF must be demethylated to THF which is metabolically active [38, 39].



FIG 10: ABSORPTION OF FOLIC ACID

BIO CHEMICAL FUNCTIONS

One -carbon metabolism - The only function of folate coenzymes in the body appears to be in mediating the transfer of one carbon units [29]. Folate coenzymes act as acceptors and donors of one-carbon units in a variety of reactions critical to the metabolism of nucleic acids (RNA and DNA), cell division and certain amino acids [30].

Nucleic acid metabolism - Folate coenzymes play a vital role in DNA metabolism through two different pathways.

- The synthesis of DNA from its precursors (thymidine and purines) is dependent on folate coenzymes.
- A folate coenzyme is required for the synthesis of methionine, and methionine is required for the synthesis of S-adenosylmethionine (SAM). SAM is a methyl group (one-carbon unit) donor used in many biological methylation reactions, including the methylation of a number of sites within DNA and RNA [31].

Amino acid metabolism - Folate coenzymes are required for the metabolism of several important amino acids such as methionine, histidine, serine, and glycine. The synthesis of methionine from homocysteine requires a folate coenzyme as well as a vitamin B12-dependent enzyme [32].

CAUSES OF FOLIC ACID DEFICIENCY

- Dietary Deficiency
- Mal absorbtion
- Enzyme defect –DHFR
- Drug induced
    - (a) Trimethoprim
    - (b) Pyrimethamine
    - (c) Methotrexate
    - (d) Phenytoin

CLINICAL FEATURES

- Megaloblastic Anaemia
- Neural Tube Defects

VITAMIN B12

Cobalamin which is called as vitamin B12 is a member of B complex group of vitamins. It plays a vital role in blood, brain, nerve function. . The richest sources of vitamin B12 are meat and egg. Milk, fortified cereals, fish are some of the rich sources of vitamin B12. So vegetarians are at the risk of developing vitamin B12 deficiency.

The daily required adult dose is around 1-3 microgram, which is only 0.1% of total body store. The total body stores are of 2-3 milligram. So the total body store is sufficient almost for half a decade, in the absence of external supplies.

STRUCTURE

The structure of B12 is based on a corrin ring, which is similar to the porphyrin ring found in heme, and cytochrome. The central metal ion is cobalt. Four of the six coordination sites are provided by the corrin ring, and a fifth by a dimethylbenzimidazole group. The sixth coordination site, the center of reactivity, is variable, being a cyano group (-CN), a hydroxyl group (-OH), a methyl group (-CH3) or a 5'-deoxy adenosyl group, respectively, to yield the four B12 forms mentioned above.



FIG 11: STRUCTURE OF VITAMIN B12 [57]

ABSORPTION AND TRANSPORT

There are two mechanisms by which vitamin B12 is absorbed. Passive process occurs through small intestine mucosa. But passive process is highly inefficient and extremely fast [41]. Thus the normal physiological absorption process occurs by active diffusion at the level of terminal ileum in the presence of gastric intrinsic factor. Cobalamin in the diet is separated from its protein complexes by the action of gastric and small intestinal enzymes [42]. Then it binds to the R- binder with which it is transported to the terminal ileum. Intrinsic factor is secreted from stomach parietal cells. It combines with cobalamin and forms IF-Cobalamin complexes and transported to terminal ileum. This complex attaches itself to receptor cubilin. It is an endocytic receptor protein which helps in the translocation of complex into the enterocytes, where the intrinsic factor is destroyed. With a lag period of six hours cobalamin appears in the portal circulation combined with transcobalamin II [43].

High amount of cobalamin undergoes enterohepatic circulation from the denuded intestinal epithelial cells. Hence the risk of this vitamin deficiency is higher in patients with malabsorption than in vegetarians. The transport of cobalamin occurs in one to one molecule manner. Transcobalamin I is formed from the granules of neutrophils. It has no primary role in transport of cobalamin into the tissues. The major transport protein is transcobalamin II. It is produced from the liver endothelial cells, ileal enterocytes and macrophages. This takes up cobalamin to areas of high demand like marrow, placenta [44, 45].



FIG 12: ABSORPTION OF VITAMIN B12

CLINICAL MANEFISTATIONS OF VITAMIN B12 DEFICIENCY

TYPE	CLINICAL MANEFISTATIONS
Hematological	Macrocytosis (frequent)
	Isolated thrombocytopenia and Neutropenia, Pancyteopenia (rare)
Neuropsychiatric	Combined degeneration of the spinalcord(classic)
	Peripheral neuropathy (frequency)
	Ataxia
	Optic atrophy(rare)
	Dementia
	Psychosis, depression

CAUSES OF VITAMIN B12 DEFICIENCY [40]

- Dietary Deficiency
- Mal absorption
- Genetic defects –Transcobalamin deficiency
- Drug induced

    (a) Trimethoprim

    (b) Metformin

    (c) Methotrexate

    (d) Pantoprazole



FIG 13: MAJOR REACTIONS INVOLVING VITAMIN B12

PHYSIOLOGICAL ROLE OF VITAMIN B12

Cbl has 2 known cofactor actions: {A} Transfer of a methyl group from Methyl tetra hydro folate (THF) via Cbl to homocysteine to form methionine - this reaction has 2 important effects: it reduces the plasma concentration of homocysteine which is

probably toxic to endothelial cells; and it demethylates THF [46]. Demethylation is a critical step in DNA synthesis because THF (the reduced form of folate) and not methyl-THF is the substrate for the enzyme that converts (THF)-1 to the polyglutamated form, (THF) n.

{B} Conversion of propionyl-Co Acetate (CoA) to methylmalonyl CoA and finally to succinyl-CoA. There is no interaction with FA in this pathway; as a result, it has been proposed that this pathway might be important in myelin formation and in the neurologic abnormalities seen with B12 but not FA deficiency.

Two hypotheses have been developed to explain how vitamin b12-deficiency anaemia is in fact caused by functional folate deficiency.[33.34]

- **Methyltetrahydrofolate trapping, or the ‘‘folate trap’’.**

Without cobalamin, homocysteine level gets elevated in the circulation. Methyltetrahydrofolate cannot be demethylated to form tetrahydrofolate .So folate gets trapped. When folate gets trapped, stored methyltetrahydrofolate can-not be converted into polyglutamisable formate-mediated formyltetrahydrofolate, which is another functional form of folate used in purine synthesis.

In addition to the foregoing hypotheses, the metabolism of vitaminb12 and folic acid share another common feature: they both require methylenetetrahydrofolate (a product of tetrahydrofolate) and dUMP to form thymidylate synthase-mediated thymidylate and dihydrofolate.

For the reasons stated above, tetrahydrofolate cannot occur without cobalamin, and without tetrahydrofolate, neither methylenetetrahydrofolate nor its product, thymidylate, can occur.[35, 36]



FIG 14: FOLATE TRAP

EFFECT OF PHENYTOIN ON FOLATE AND VITAMIN B12

Phenytoin alters the bio-availability and metabolism of Folate and Vitamin B12 by the following mechanism [37, 38].

- Phenytoin increases the pH of the small intestine inhibiting the intestinal conjugase activity thereby impairing the conversion from polyglutamate folate (inactive) into monoglutamate folate (active), leading to lower absorption of folate[39].
- Phenytoin sodium was similar to folate in the structure, thus there was a competition between two drugs, leading to decreased folate binding to the folate receptors on intestinal mucosal cells and decrease absorption of folate[40].
- Phenytoin sodium may decrease the activity of folate metabolizing enzymes, such as methylene synthase; as a result the synthesis of folate was impaired.

- Phenytoin increases the activity of hepatic microsomal enzymes, thereby accelerating the metabolism of folate and decreases the level of folate in the body[1].
- The above hypothesis clearly shows that phenytoin does not affect Vitamin B12 metabolism directly.
- Since some of the action of Vitamin B12 is dependent on folate cofactor, any alteration in the level of B12 by phenytoin is related to the phenytoin induced folate deficiency. This is based on the observation that the administration of folic acid resulted in elevation of Vitamin B12 level in epileptic patients.
- Both folate and Vitamin B12 deficiency by phenytoin ultimately leads to megaloblastic anemia.



FIG 15: RELATIONSHIP BETWEEN COBALAMIN AND FOLATE DEFICIENCY

LABORATORY DIAGNOSTIC APPROACH TO MEGALOBLASTIC ANAEMIA

The following laboratory investigations are needed to diagnose megaloblastic anaemia:

1. Complete Blood Count
2. Peripheral Smear Study
3. Estimation of Serum Vitamin B12 and Folate Level

In addition to these investigations following tests are needed for confirmatory diagnosis of megaloblastic anaemia.

4. Bone-marrow examination
5. Measurement of Serum methyl malonic acid (MMA) and Homocysteine

1. COMPLETE BLOOD COUNT

The degree of elevation of the MCV is often a clue to diagnosis of megaloblastic anaemia caused by vitamin B12and folic acid deficiency. Thus, the probability of a deficiency of folate and/or Cbl being present when the MCV is 80 to100fl (normal),100 to 105(mild) 106 to115(mod) and >116 fl(severe) been estimated at <25, 50, 75 and 100 percent, respectively[51,52]. Unless a combined deficiency (eg, iron deficiency plus a deficiency of Cbl and/or folate) is suspected, routine testing for Cbl or folate deficiency in an anemic patient in the presence of a MCV <80 fL is not likely to be productive.

2. PERIPHERAL BLOOD SMEAR

I. Macroovalocytes , hypersegmented neutrophils (earliest change), basophilic stippling, occasional megaloblast

II. Peripheral pancytopenia



FIG 16: PERIPHERAL BLOOD SMEAR

B12 LEVELS

Several commercial laboratories use different methods (chemiluminescence or radio assay) for measuring Cbl. As a result, there are different normal ranges and there is no single "gold standard" [42]. B12 deficiency can be classified, based on its serum levels, as [47, 48, 49]:

1. **>300** pg/mL (>221 pmol/L) — **normal**; Cbl deficiency is unlikely. (ie,1 to 5%)
2. **200 to 300** pg/mL (148 to 241 pmol/L) — **borderline**; Cbl deficiency possible
3. **<200** pg/mL (<148 pmol/L) — **low**; consistent with Cbl deficiency (specificity of 95-100%). However U.S. clinical laboratories regard 200 pg /ml as the lower range of normal.

FOLATE LEVEL

Several commercial laboratories use different methods (chemiluminescence or radio assay) for measuring Folate as like vitamin B12.

- <2 ng/mL is diagnostic of folate deficiency
- >4 ng /mL rules out deficiency of folate

MEASUREMENT OF MMA AND HC

- Serum concentrations of homocysteine (HC) and methylmalonic acid (MMA) are elevated in Cbl deficiency, due to a decreased rate of metabolism.
- HC is elevated in folate deficiency, since folate does not participate in MMA metabolism [50].

BONE MARROW EXAMINATION

Bone marrow aspiration and biopsy reveal hypercellular marrow with megaloblastic erythroid hyperplasia and giant hypersegmented metamyelocytes due to inadequate conversion of deoxyuridate to thymidylate, which leads to slowing of DNA synthesis and delayed nuclear maturation [53].

Thus by determining the serum level of Vitamin B12 and Folate annually in the epileptic patients on phenytoin monotherapy, anaemia can be prevented earlier by supplementing with vitamin B12 and folate to the patients.

AIM AND OBJECTIVES

AIM AND OBJECTIVES

AIM

The aim of this study is to estimate the level of vitamin B12 and Folic acid in epileptic patients on phenytoin monotherapy.

OBJECTIVES

- To estimate the serum vitamin B12 and Folic acid level in patients on phenytoin monotherapy.
- To study the prevalence of Vitamin B12 and Folate deficiency in epileptic patients on phenytoin monotherapy.
- To assess the relation between phenytoin monotherapy duration and development of Vitamin B12 and Folate deficiency.

MATERIALS AND METHODS

MATERIALS AND METHODS

STUDY CENTRE:

- Department of Neurology
- Department of Biochemistry
- Stanley Medical College & Hospital

DURATION OF THE STUDY:

- 6 months (January 2018 to June 2018)

STUDY DESIGN:

- Cross Sectional Study

STUDY POPULATION:

- Epileptic Patients on Phenytoin monotherapy

SAMPLE SIZE: 100

INCLUSION CRITERIA:

- Epileptic patients on phenytoin monotherapy

EXCLUSION CRITERIA:

- Age < 18 years
- Pregnancy
- Heart, Liver and Kidney dysfunction
- Drugs- oral contraceptives, Pantoprazole and Methotrexate
- Alcohol and Smoking

This study was approved by institutional ethical committee of Government Stanley Medical College, Chennai. After full explanation of the study, the written informed consent was obtained from each participant.

STUDY PROCEDURE

Patients, who meet the inclusion criteria, after getting informed consent, were divided into two groups.

1. **Control:** Newly diagnosed epileptic patients on phenytoin monotherapy < 1 Year.
2. **Cases:** Epileptic patients on phenytoin monotherapy > 1 year.

METHODS

After getting informed consent from the patients, under strict aseptic precautions 5 ml of random blood sample was collected. 3 ml of blood taken in plain red topped veni puncture tubes without any additives or gel barrier. Remaining 2 ml of blood was taken in EDTA tubes for complete blood count and peripheral smear examinations. Collected samples were centrifuged at 2000-2500 rpm for 10 min and Serum separated immediately and stored at -20^{o} Celsius in deep freezer for estimation of Vitamin B12 and Folic Acid.

Study population was examined and routine blood investigations-Glucose, Urea, and Creatinine were done in their blood sample followed by special investigations like:

1. **COMPLETE BLOOD COUNT**

    - Hemoglobin
    - Total WBC Count
    - Differential Count
    - RBC
    - Platelet Count
    - MCV
    - MCH
    - MCHC

2. **PERIPHERAL BLOOD SMEAR STUDY**

3. **SERUM FOLIC ACID**

4. **SERUM VITAMIN B12**

ESTIMATION OF PLASMA GLUCOSE

METHOD: Glucose Oxidase Peroxidase (GOD / POD) (End Point Test)

KIT USED: Erba

PRINCIPLE:

Glucose Oxidase

Glucose + $O2+_{H2O}$ ⟶ Gluconic acid + H2 O

Peroxidase

H2O2+4APP+PHENOL ⟶ Pink complex +H2O

Pink coloured Quinonemine complex is developed depending on the glucose concentration in the sample. Absorbance was read at 505 nm.

COMPOSITION OF REAGENTS

REAGENT -1: ENZYME REAGENT

- Peroxidase -> 2000U/L
- Glucose Oxidase - 20000U/L
- Phosphate buffer - 200 mmol/
- L Phenol - 10 mmol/L

GLUCOSE STANDARD - 100 mg/dl

PROCEDURE: 10µl of plasma was added to 1000µl of working reagent and incubated at 37 degree celcius for 15 minutes.

REFERENCE RANGE: Fasting plasma glucose 70 - 110mg/dl

ESTIMATION OF BLOOD UREA

KIT USED: Erba

METHOD: Urease - GLDH (kinetic UV test)

PRINCIPLE:

Urea is hydrolysed by Urease in the presence of water which produces ammonia and carbon dioxide. In the presence of glutamate dehydrogenase the ammonia reacts with NADH and oxoglutarate to give glutamate and NAD.

$$\text{Urea} + H_2O \xrightarrow{\textit{Urease}} 2NH_4^+ + H_2O$$

$$NH_4^+ + \text{NADH} + H^+ + \text{2-oxoglutarate} \xrightarrow{\text{GLDH}} \text{Glutamate} + \text{NAD}$$

The rate of decrease in the NADH concentration is directly proportional to the urea concentration in the specimen and is measured photometrically at 340 nm.

COMPOSITION OF REAGENT:

- Reagents I: Buffer reagent
- Reagent II: Enzyme reagent
- Urea standard: 50 mg/dl

PREPARATION OF REAGENT:

- 1ml of Enzyme is taken along with4 ml of Buffer reagent both mixed gently.

METHODS:

10µl of plasma is added to 1000µl of reconstituted reagent Mix well and read after 30secs (initial absorbance of sample A1s and standard A1std) and read again after 60secs (A2s and A2std). Tests were assayed on Beckman Coulter AU 480 auto analyzer after calibration.

REFERENCE RANGE: Serum / Plasma Urea → 15 – 39 mg/dl.

ESTIMATION OF CREATININE

KIT USED: Erba

METHOD: Modified Jaffe's method

PRINCIPLE:

Creatinine present in serum or urine reacts with alkaline picrate to form colored complex. The rate of formation of colored complex is directly proportional to creatinine concentration.

Creatinine + Alkaline Pictrate ⟶ Creatinine Picrate Complex

COMPOSITION

Reagent 1:

- Picric Acid Reagent
- Picric Acid - 25.8 mmol/L

Reagent 2:

- Sodium Hydroxide – 95 mmol/L
- Sodium Hydroxide Reagent

STANDARD:

- 2mg/dl (0.166 mmol/L)

PREPARATION OF REAGENT:

- Equal volume of both the reagents mixed and used after 15 minutes.

PROCEDURE:

100µl of the sample is added to 1000µl of the reconstituted reagent and mixed gently and immediately the reading is taken. Difference in the initial absorbance at 20 sec's and final absorbance after 80 sec's are recorded at 510 nm.

REFERENCE RANGE:

Male: 0.6 – 1.1 mg/dl,

Female: 0.5 – 0.9 mg/dl.

ESTIMATION OF SERUM VITAMIN B12

EQUIPMENT:

- Cobas e 411/601 Analyzer

REAGENTS

- The reagent working solutions include:
    - The rack pack (kit placed on instrument)
    - Streptavidin coated micro-particles,
    - Reagent 1 (ruthenium labeled intrinsic factor) and
    - Reagent 2 (vitamin B12 labeled biotin)
    - Pretreatment 1 (Dithiothreitol)
    - Pretreatment 2 (sodium hydroxide, sodium cyanide)

METHODS

Electro-chemiluminescence immunoassay (**ECLIA**) for in vitro Quantitative determinations of vitamin B12 and Folic Acid in human serum were performed using Automated Cobas e411 Immunoassay Analyzers based on electro chemiluminescent technology using ruthenium complex and the measuring cell. 'Electro' means electrical stimulation 'chemi 'refers to chemical reaction and luminescence indicates production of light.

FIG 17: COBAS e 411 – ANALYSER

PRINCIPLE:



COMPETITION PRINCIPLE

- Total duration of assay**:** 27 minutes.

1ST INCUBATION: (9 Mins)

15 µl of sample is incubated for 9 Mins with pretreatment 1 and 2 so as to release the bound vitamin B12.

2ND INCUBATION: (9 Mins)

Above pretreated sample is incubated with the ruthenium labeled intrinsic factor to form a vitamin B12-binding protein complex. The amount of this complex depends on the analyte concentration in the sample.

3RD INCUBATION: (9 Mins)

The above complex reacts with streptavidin-coated micro particles and vitamin B12 labeled with biotin to form ruthenium labeled intrinsic factor-vitamin B12 biotin complex. The entire complex becomes bound to the solid phase via interaction of biotin and streptavidin.



FIG 18: THE MAGNET ATTRACTS THE PARAMAGNETIC BEADS THUS BINDING THE COMPLEX

The reaction mixture is aspirated into the measuring cell where the micro particles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with procell. Then, the procell applied, which separates the particles bound to immunocomplex from the free particles. The procell also provides tripropylamine [TPA] which is essential for the electrochemi - luminescence [ECL] reaction to take place.



FIG 19: TPA ENABLE RUTHENIUM TO REDUCE TO ITS BASE STATE WITH RELEASE OF LIGHT

Results are determined with the help of a calibration curve generated by 2-point calibration.

REAGENT:

- Vitamin B12 Elecsys from Roche Diagnostics

STORAGE AND STABILITY:

- Store at 2-8 °C. Do not freeze.

REFERENCE RANGE: [54]

- 200-700 pg/ml

ESTIMATION OF FOLIC ACID



PRINCIPLE – COMPETITIVE ASSAY

- Total duration of assay: 27 minutes

1ST INCUBATION: (9 MINS)

25 µl of sample is incubated for 9 Mins with pretreatment 1 and 2 so as to release the bound folate.

2ND INCUBATION: (9 MINS)

Above pretreated sample is incubated with the ruthenium labeled intrinsic factor to form a ruthenium labeled folate-binding protein complex. The amount of this complex depends on the analyte concentration in the sample.

3RD INCUBATION: (9 MINS)

The above complex reacts with streptavidin-coated micro particles and folate labeled with biotin to form ruthenium labeled intrinsic factor-vitamin B12 biotin

complex. The entire complex becomes bound to the solid phase via interaction of biotin and streptavidin.

MEASUREMENT

The reaction mixture is aspirated into the measuring cell where the micro-particles are magnetically captured onto the surface of the electrode. Unbound substances are then removed. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.

Results are determined with the help of a calibration curve generated by 2-point calibration.

REAGENT:

- Folate Reagent from Roche Diagnostics

STORAGE AND STABILITY:

- Stability
- Unopened at 2 to 8 °C – upto stated expiry date
- After opening at 2 to 8 °C – 12 weeks
- On the analyzer – 8 weeks
- Store at 2 to 8 °C

REFERENCE RANGE: [54]

- 4-20 ng/ml

CALIBRATION:

Calibration performed once per reagent lot using fresh reagent. Two set of two levels of calibrators CAL 1 and CAL 2 are provided in separate kit for each analyte.





FIG 20: L – CALIBRATION WAS GENERATED FOR VITAMIN B12 AND FOLIC ACID.



FIG 21: **QUALITY CONTROL MATERIAL FOR VITAMIN B12**



FIG 22**: QUALITY CONTROL FOR VITAMIN B12 AND FOLIC ACID**

COMPLETE BLOOD COUNT

Complete hemogram is obtained in our clinical pathology lab using SYSMEX KX-cell counter. Cell counters enumerates cells in a small aperture by measuring changes in the electrical resistance as the cell passes through the aperture. This principle is called APERTURE-IMPEDANCE METHOD. Data generated include a three part white cell differential (absolute count, percentage) in addition to red cell counts, WBC count, platelet count, Hb, hematocrit, MCV, MCH, MCHC, RDW.

FIG 23: AUTOMATED ANALYSER

MCV, MCHC, MCH: RED CELL INDICES - estimated by auto analyser

(i) $$MCV = \frac{PCV * 10}{RBC \text{ in million per cumm}}$$

80 – 97 FL – Normal

< 80- microcytic

>97 – macrocytic

(ii) $$MCH = \frac{Hb * 10}{RBC \text{ in million per cumm}}$$

27 – 31(pg) - Normal

< 27 – Hypo chromic

> 31 - Hyper chromic

(iii) $$MCHC = \frac{Hb * 100\ (\%)}{PCV}$$

32 – 36 % - Normal

< 32 Hypo chromic

> 36 – Hyper chromic

PERIPHERAL SMEAR FOR BLOOD PICTURE

Using Leishmann's stain blood smear was examined with a lab microscope by oil immersion field

STATISTICAL ANALYSIS & RESULTS

RESULTS

In this study 100 epileptic patients on phenytoin monotherapy were evaluated. According to the duration of phenytoin treatment they were divided into cases and control. Cases include 50 epileptic patients on phenytoin monotherapy more than one year duration. Control includes 50 epileptic patients on phenytoin monotherapy less than one year duration.

Results of laboratory parameters obtained from cases were compared with controls by statistical analysis using excel software. Students unpaired‘t’ test was used to compare the mean between two independent groups. Pearson’s correlation coefficient was used to estimate the degree of association between two quantitative variables. A p value of < 0.05 considered as statistical significant.

TABLE 1:

AGE DISTRIBUTION FOR CASE

Age	No. of Patients	Percentage
18-25	9	18
26-50	29	58
>50	12	24



FIG 24: SHOWS DIFFERENT AGE-WISE DISTRIBUTION OF CASES

The table 1 shows the different age distribution for cases. Maximum percentage of participants lies in the age group of 26-50 years.

TABLE 2:

AGE DISTRIBUTION FOR CONTROL

Age	No. of Patients	Percentage
18-25	15	30
26-50	20	40
>50	15	30



FIG 25: SHOWS DIFFERENT AGE-WISE DISTRIBUTION OF CONTROL

The table 2 shows the different age distribution of controls. Maximum percentage of participants lies in the age group of 26-50 years.

TABLE 3:

AGE DISTRIBUTION AMONG THE CASE AND CONTROL GROUP

Group	Number	Mean Age(Years)	Standard Deviation	Student t-Test
Case	50	38.12	12.9	P=0.36 Not Significant
Control	50	39.66	14.7	

No statistical significance (P=0.36) was obtained with regards to age distribution among cases and control in Table 3.Hence both the groups are comparable.

TABLE 4:

SEX DISTRIBUTION FOR CASE

Age	No. of Patients	Percentage
Male	35	70
Female	15	30



FIG 26: SHOWS MAXIMUM PERCENTAGE OF CASES ARE MALE

TABLE 5:

SEX DISTRIBUTION FOR CONTROL

Age	No. of Patients	Percentage
Male	30	60
Female	20	40



FIG 27: SHOWS MAXIMUM PERCENTAGE OF CONTROL ARE MALE

TABLE 6:

SEX DISTRIBUTION OF DIFFERENT AGE GROUP FOR CASE

AGE	No. of Patients	Men (%)	Women (%)
18-25	9	88.88	11.11
26-50	29	65.51	34.48
>50	12	66.66	33.33



FIG 28: SHOWS SEX DISTRIBUTION IN DIFFERENT AGE GROUP FOR CASE

TABLE 7:

SEX DISTRIBUTION IN DIFFERENT AGE GROUP FOR CONTROL

Age	No. of Patients	Men (%)	Women (%)
18-25	15	46.66	53.33
26-50	20	65	35
>50	15	60	40



FIG 29: SEX DISTRIBUTION IN DIFFERENT AGE GROUP FOR CONTROL

TABLE 8

STATISTICAL ANALYSIS FOR GLUCOSE, UREA, CREATININE

Parameter	Control		Cases		P Value
	Mean	SD	Mean	SD	
Glucose	138.24	25.95	142.33	41.24	0.575 (Not significant)
Urea	27.16	6.34	28.17	8.70	0.528(Not Significant)
Creatinine	1.02	0.26	0.86	0.40	0.035(Significant)

TABLE 9:

DURATION OF PHENYTOIN THERAPY AMONG STUDY PARTICIPANT

Duration	Group	Count	Mean	Standard Deviation	P Value
>1 Year	Cases	50	8.64	3.8	0.55 Not Significant
<1 Year	Control	50	8.22	4.1	



FIG 30: SHOWS MEAN ± SD OF CASES > CONTROL WITH REGARD TO DURATION OF PHENYTOIN THERAPY

In table 7, No statistical significance (p=0.55) was obtained with regards to duration of phenytoin monotheraphy between cases and control.

TABLE 10:

SIGNIFICANCE OF VITAMIN B12 LEVEL

Group	Count	Mean	Standard Deviation	P Value
Cases	50	284.68	110.12	0.01
Control	50	469.44	154.32	

Table 8 shows significant difference between the mean values of vitamin B12 in the cases and control . (p=0.01)



FIG 31: SHOWS THE SIGINIFICANCE OF MEAN BETWEEN CASES AND CONTROL

TABLE 11:

SIGNIFICANCE OF FOLIC ACID LEVEL

Group	Count	Mean	Standard Deviation	P Value
Cases	50	2.61	1.81	<0.000
Control	50	7.01	4.40	



FIG 32: SHOWS THE SIGINIFICANCE OF FOLIC ACID LEVEL BETWEEN CASES AND CONTROL

Table 9 shows significant difference between the mean values of Folic Acid in the Cases and Control. ($p<0.000$)

TABLE 12:

VITAMIN B12 LEVEL DEPENDING ON THE DURATION OF PHENYTOIN TREATMENT

Duration	Count	Mean	Standard Deviation	P Value
2-5	14	315.25	114.76	0.23
>5-10	29	283.93	112.52	
>10	7	227.99	74.04	



FIG 33: SHOWS DECREASE IN MEAN OF VITAMIN B12 LEVEL ACCORDING TO DURATION OF PHENYTOIN TREATEMENT

TABLE 13:

FOLIC ACID LEVEL DEPENDING ON THE DURATION OF PHENYTOIN TREATMENT

Duration	Count	Mean	Standard Deviation	P Value
2-5	14	3.86	2.95	0.004
>5-10	29	2.27	0.65	
>10	7	1.5	0.36	



FIG 34: SHOWS DECREASE IN MEAN OF FOLIC ACID LEVEL ACCORDING TO DURATION OF PHENYTOIN TREATEMENT

TABLE 14:

CORRELATION OF RED CELL INDICES WITH DURATION OF PHENYTOIN

Variable	Cases	Control	P-Value
	Mean± SD	Mean± SD	
HB	9 ± 2.12	11.2±2.3	0.5
MCV	84±13.5	77.9±13.3	0.9
MCH	26±4.88	26.5±4.09	0.2
MCHC	32±3.41	33.2±8.92	<0.00001



FIG 35: CORRELATION OF RED CELL INDICES BETWEEN CASES AND CONTROL WITH DURATION OF PHENYTOIN TREATMENT

Figure 9 shows decrease in the mean of HB level and increase in the mean of MCV level between cases and control.

TABLE 15:

DISTRIBUTION BASED ON PERIPHERAL SMEAR PICTURES

CASES	COUNT
Macrocytic Cells	14
Microcytic Cells	15
Normal	21



FIG 36: SHOWS THE PERIPHERAL SMEAR FINDINGS OF CASES

TABLE 16:

DISTRIBUTION BASED ON PERIPHERAL SMEAR PICTURES

CONTROL	COUNT
Macrocytic Cells	3
Microcytic Cells	22
Normal	25



FIG 37: SHOWS PERIPHERAL SMEAR FINDINGS OF CONTROL

TABLE 17:

HB LEVEL DISTRIBUTION FOR CASE

HB LEVEL	Total Patients	No. Of Men	No. Of Women	Male (%)	Female %)
Mild (>10)	17	11	06	64.70	35.29
Moderate (7-10)	20	13	07	65	35
Severe(<7)	13	11	02	84.61	15.38



FIG 39: HB LEVEL DISTRIBUTION OF CASES AMONG THE PARTICIPANTS

TABLE 18:

HB LEVEL DISTRIBUTION FOR CONTROL

HB LEVEL	Total Patients	No. Of Men	No. Of Women	Male (%)	Female %)
Mild (>10)	37	25	12	67.56	32.43
Moderate (7-10)	11	4	7	36.36	63.63
Severe(<7)	2	1	1	50	50



FIG 40: HB LVEL DISTRIBUTION OF CONTROL AMONG THE PARTICIPANTS

TABLE 19

PREVALENCE OF VITAMIN B12 AND FOLATE DEFICIENCY AMONG CASES AND CONTROL

Group	Number of Participants	Vitamin B12 Deficiency	Folate Deficiency	Combined Deficiency
Cases	50	11	18	11
Control	50	0	3	3



FIG 41: PREVALENCE OF VITAMIN B12 AND FOLATE DEFICIENCY AMONG CASES AND CONTROL

REGRESSION ANALYSIS BETWEEN DURATION OF PHENYTOIN TREATMENT AND VITAMIN B12 LEVEL IN CASES

Y= 9.11X+363.6
r =- 0.09



X= Duration of Phenytoin (Years)

Y= Vitamin B12 (pg/ml)

The above graph explains the correlation of Vitamin B12 with duration of phenytoin treatment. Vitamin B12 values have negative correlation with duration of phenytoin as linear regression analysis has downward slope and r value = -0.09.

REGRESSION ANALYSIS BETWEEN DURATION OF PHENYTOIN TREATMENT AND FOLIC ACID LEVELS IN CASES

Y= 0.020X+4.42
r = -0.19



X=Duration of Phenytoin (Years)

Y=Folic Acid Level (ng/ml)

The above graph explains the correlation of Folate level with duration of phenytoin treatment. Folate values have negative correlation with duration of phenytoin as linear regression analysis has downward slope and r value = -0.19.

TABLE 20:

CORRELATION OF VITAMIN B12 AND FOLATE LEVEL WITH DURATION OF PHENYTOIN IN EPILEPTIC PATIENTS AMONG CASES

Variables	Pearson's Correlation Coefficient (r)	Significance (p)	Interpretation
Vitamin B12 Vs Duration	-0.09	0.02	Significant and Negative correlation
Folate Vs Duration	-0.19	0.001	Significant and Negative Correlation

REGRESSION ANALYSIS BETWEEN DURATION OF PHENYTOIN TREATMENT AND VITAMIN B12 LEVEL IN CONTROL

Y= = 1.508*X + 457.0
r= 0.00



X= Duration of Phenytoin (Years)

Y= Vitamin B12 Level (pg/ml)

The above graph explains the correlation of vitamin B12 with duration of phenytoin treatment. Vitamin B12 have no correlation with duration of phenytoin and r value = 0.00.

REGRESSION ANALYSIS BETWEEN DURATION OF PHENYTOIN TREATMENT AND FOLIC ACID LEVELS IN CONTROL

Y = -0.06725*X + 7.563
r=0.00



X=Duration of Phenytoin

Y=Folic Acid Level

The above graph explains the correlation of Folate level with duration of phenytoin treatment. Folate have no correlation with duration of phenytoin and r value = 0.00.

TABLE 21:

CORRELATION OF VITAMIN B12 AND FOLATE LEVEL WITH DURATION OF PHENYTOIN IN EPILEPTIC PATIENTS AMONG CONTROL

Variables	Pearson's Correlation Coefficient (r)	Significance (p)	Interpretation
Vitamin B12 Vs Duration	0.00	0.78	Not Significant and No Correlation
Folate Vs Duration	0.00	0.66	Not Significant and No Correlation

DISCUSSION

DISCUSSION

Phenytoin is the most commonly prescribed drug for the treatment of epilepsy. It causes deficiency of folate and vitamin B12 when taken for a prolonged period (>1year). Vitamin B12 and folic acid plays a vital role in many cellular processes.There are proposed mechanisms through which phenytoin interacts with vitamin B12 and folate absorption Deficiency of both vitamins causes megaloblastic anaemia. Over 50 % of patients on long term phenytoin therapy demonstrate low serum level of vitamin B12 and folic acid. Hence in this cross sectional study, 100 epileptic patients were enrolled and they were divided into two groups. Those who were taking phenytoin drug more than one year were considered as cases, whereas patients on phenytoin drug less than one year were taken as controls. The serum vitamin B12 and folate levels were measured and correlated with the duration of phenytoin therapy.

In the present study the mean age of the control was 39.66 ± 14.7 years and for the study group the mean age was 38.12 ± 12.9 years. The two groups were found to be age matched (TABLE**-3**). Phenytoin was used predominantly among patients between 30 to 50 years of age in this study. The total numbers of male and female were almost equally distributed between cases and controls.

In this study the mean of serum vitamin B12 and folate level were compared by unpaired student's t test. The mean value of serum B12 level in the study group (284.68 ± 110.12) showed a statistically significant fall of 39.4 % compared to mean value of control group (469.44 ± 154.32) and p value 0.01(TABLE 9). This finding is consistent with a result of study by Linnebank et al (2011), Sener (2006), Majola

(2000).The decrease in vitamin B12 level is due to the effect of phenytoin on bioavailability and metabolism of vitamin B12. [18, 20]

The present study revealed decrease in the mean of vitamin B12 level with increase in duration of phenytoin treatment among cases compared to control. Among cases the mean level of vitamin B12 at (2-5 years) phenytoin treatment is (315.25±114.76), for 5-10 years is (283.93± 112.52) and > 10 years is (227.99 ± 74.04).(TABLE 11). This finding is consistent with the result of study by Linnebank et al (2011), Sener 2006).

In the present study the mean value of serum folate level in the study group (2.61± 1.81) showed a statistically significant fall of 62.8 % compared to mean value of control group (7.01± 4.40) the p-value (< 0.00001)(TABLE 10).The decrease in folic acid level is due to the effect of phenytoin mainly on inhibiting the intestinal absorption of folate [1].

The present study revealed decrease in the mean of folic acid level with increase in duration of phenytoin treatment among cases compared to control Among cases the mean level folic acid at 2-5 years of treatment is (3.86±2.95) at 5-10 years (2.27±0.65) and >10 years is (1.5±0.36) and p-value is 0.004 which is statistically significant (TABLE 12). This clearly shows that the level of Serum folic acid decreases with increasing duration of phenytoin treatment which is consistent with finding of Kishi et al, Bailey (2005), Davis (2002) who found the similar results in his study.

This study also shows decrease in the mean of Hb among cases (9±2.12) than control (11.2±2.3). 10 out of 50 patients among cases had high MCV (>100fl). Among the cases 14 had macrocytosis demonstrated by peripheral smear picture. 16 have microcytic pictures and 20 had normal smear picture. Mean MCH was similar in among cases and control. Mean MCHC was low in cases (32±3.41) compared to control (33.2±8.92) which may correlate with decrease hemoglobinization with increased cell size in macrocytosis patients.

Out of 50 participants among cases, 11 had Vitamin B12 deficiency (<200 pg/ml) and 18 had folate deficiency (<2 ng/ml) and 11 had both Vitamin B12 and folate deficiency. Among control only 3 had folate deficiency and there was no vitamin B12 deficiency. Thereby the prevalence of folate and vitamin B12 deficiency among cases were 36%and 22% whereas in control the prevalence rate was 6%. This shows that vitamin deficiency is increased among cases compared to control. This finding is consistent with the study of Rivey MP et al which states that Folate deficiency resulting from long term phenytoin therapy was a common occurrence, but the progression of deficiency to megaloblastic anemia was rare.

The current study revealed a statistically significant negative correlation between vitamin B12 level and duration of Phenytoin treatment(r= 0.09, p=0.02) among cases (TABLE 18). It indicates that vitamin B12 levels decrease with increase in duration of phenytoin treatment. This result is concordant with the study of Linnebank et al 2011 who also found similar result in his study.

This study also revealed a statistically significant negative correlation between folate level and duration of phenytoin treatment(r= 0.19, p=0.001) among cases (TABLE 18). It indicates that folate levels decrease with increase in duration of phenytoin treatment. This result is concordant with the study of Linnebank et al 2011 who also found similar result in his study.

SUMMARY

SUMMARY

The study on effect of antiepileptic drug phenytoin on folic acid and vitamin B12 level in epileptic patients was conducted in our tertiary care hospital.

100 epileptic patients were included in our study. They were divided into case and control according to the duration of phenytoin treatment. After getting careful history and examinations, blood sample was collected for estimating vitamin B12 and folate level, and for complete blood count and peripheral smear study.

The level of vitamin B12 and folic acid was estimated by immunoassay method. The correlation between vitamin B12 and folic acid level with duration of phenytoin treatment was studied.

Folic acid and vitamin B12 levels decreased in patients on phenytoin therapy (>1year) compared to controls. The level of vitamin B12 and folic acid decreased with increase in duration of phenytoin treatment (>1year) compared to control.Thus the prevalence of folic acid and vitamin B12 deficiency increased in patients on phenytoin therapy(>1year) . Hence, screening of folic acid and vitamin B12 level are recommended before starting phenytoin therapy or if phenytoin therapy is advised for prolonged period so that anaemia can be prevented earlier by supplementing vitamins to the patients.

CONCLUSION

CONCLUSION

From the results of our study we conclude that epileptic patients on long term phenytoin monotherapy showed lower level of serum folate and vitamin B12 compared to newly diagnose epileptic patients on phenytoin. This represented that the long term phenytoin treatment takes a possible risk of folate and vitamin B12 deficiency. This study highlights the need of testing vitamin B12 level and folic acid levels when patients are prescribed phenytoin therapy for longer period.

This study recommends baseline estimation of vitamin B12 level and folic acid level in epileptic patients before starting phenytoin therapy. It also recommends annual screening of vitamin B12 and folic acid level if phenytoin therapy is advised for prolonged period so that early occurrence of anaemia can be prevented by supplementing vitamin B12 and folate to epileptic patients during the treatment period.

FUTURE PERSPECTIVE

The findings of this study are only suggestive. A larger sample size and further estimation of Methyl Malonic acid, Homocysteine, and Holotranscobolamin level which are metabolites of vitamin B12 can be used to confirm diagnosis of vitamin B12 and folic acid deficiency.

BIBLIOGRAPHY

1. Hong-Li Huang, Hao Zhou, Nuan Wang & Chun-Yu Yu, Effects Of Antiepileptic Drugs On The Serum Folate And Vitamin B12 In Various Epileptic Patients, Spandidos Publications 2016, 413-416.

2. Abhishek Singh Nayyar B, Nataraju and G T Subhas, Phenytoin-Folate Interactions: How Far is Safe Folate Supplementation in Phenytoin Treated Epileptic Patients?, Journal of Applied Pharmaceutical Science 02 (06); 2012: 230-235.

3. Palanisamy A, Arifa M, Narmadha MP, Rajendran NN. Folic acid level and lipid profile in epilepsy patients on antiepileptic drug treatment. Int J Pharmacol Clin Sci. 2012;1:91-96

4. Ekaidem IS, Akpanabiatu MI, Uboh FE, Eka OU (2006). Vitamin B12 supplementation: Effects on some biochemical and haematological indices of rats on phenytoin administration. Biokemistri 18(1): 31-37.

5. Harrison's, Principles of Internal Medicine, Eighteenth Edition,Mcgraw Hill Publication ,2012.

6. Fisher R, van Emde Boas W, Blume W, Elger C et al. Epileptic seizures and epilepsy: definitions proposed by the International League against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46:470–472.

7. Sridharan R. Epidemiology of epilepsy. Curr Sci 2002; 82:664-70

8. Bharucha NE. Epidemiology of epilepsy in India. Epilepsia 2003; 44:9–11.

9. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League against Epilepsy. Epilepsia 1981; 22:489–501.

10. Anthony SF, Eugene B, Dennis LK, Stephen LH. Harrison's Principles of Internal Medicine. 17th ed. USA: Mc Graw Hill Companies; 2008. Chapter 11, Neurology and Psychiatry; 2498-50:

11. Shearer P, David P. Seizures and Status Epilepticus: Diagnosis and Management in the Emergency Department. Emerg Med Prac 2006; 8:1-32.

12. American College of Emergency Physicians. Clinical policy: Critical issues in the evaluation and management of adult patients presenting to the emergency department with seizures. Ann Emerg Med. 2004; 43:605-25.

13. Martin JB. Antiepileptic drug therapy so far. Seizure 2010; 19:650-5.

14. Licata AL, Louis ED. Anticonvulsant hypersensitivity syndrome Comprehens Ther 1996; 22:152–5.

15. Ketter TA, Post RM, Theodore WH, Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999; 53:53–67.

16. Dawson KP, Jamieson A, Value of blood phenytoin estimation in management of childhood epilepsy. Arch. Dis. Child. 1971; 46(247):386-388.

17. Borofsky LG, Louis S, Kutt H, Roginsky M, Diphenylhydantoin: efficacy, toxicity and serum level relationships in children. J. Pediatr. 1972;81(5):995-1002.

18. Richens A. Clinical pharmacokinetuics of phenytoin. Clin. Pharmacokinet. 1979; 4(3):153-169.

19. Bergman U, Rane A, Sjoqvist F, Wiholm BE. Digoxin and phenytoin analyses as a part of consultations in clinical pharmacology: a study on the use of drugs. Ther. Drug Monit. 1981; 3(3):259-269.

20. Winn LM, Wells PG. Phenytoin-initiated DNA oxidation in murine embryo culture and embryo protection by the antioxidative enzymes superoxide dismutase and catalase: evidence for reactive oxygen species-mediated DNA oxidation in the molecular mechanism of phenytoin teratogenicity. Mol. Pharmacol. 1995; 48(1):112-120.

21. Kim PM, Wells PG. Phenytoin initiated hydroxyl radical formation: characterization by enhanced salicylate hydroxylation. Mol. Pharmacol. 1996; 49(1):172-181.

22. Liu L, Wells PG. Potential molecular targets mediating chemical teratogenesis: in vitro peroxidase-catalyzed phenytoin metabolism and oxidative damage to proteins and lipids in murine maternal hepatic microsomes and embryonic 9000g supernatant. Toxicol. Appl. Pharmacol. 1995; 134(1):71-80.

23. Winn LM, Wells PG. Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity. Free Radic. Biol. Med. 1999; 26(3-4):266-274.

24. Porter, R. J., and Meldrum, B. S. Antiseizure Drugs. In: Katzung, B. G., ed. Basic and clinical pharmacology 8th edn. Appleton and Lange Standford (2001): 395 – 418.

25. Rall, T. W. and Schleifer, L. S. Drugs effective in the therapy of epilepsies. In: Gilman, A. G., Rall, T. W., Nies, A. S., Taylor P. (eds). The pharmacological basis of therapeutics 8th edn. Perganon Press, New York (1990): 436 – 462.

26. Froscher, W., Maier, V., Lange, M., Wolfersolorf, M., Straub, R., Rothmeir, I., Steinert, T., Fiaux, A., Frank, U. and Grump, D. (1995) Folate deficiency, anticonvulsant drugs and psychiatric morbidity. *Clin Neuropharmacol* 18: 165 – 182.

27. Lewis, D. P., VanDyke, D. C., Willhite, L. A., Stumb, P. J., Berg, M. J. (1995) Phenytoin- Folic acid interaction. *Ann. Pharmacol.* 29: 726-735.

28. Ahmadi SA, Boroumand MA, Gohari-Moghaddam K, Tajik P, Dibaj SM. The Impact of Low Serum Triglyceride on LDL-Cholesterol. Arch. Iranian. Med. 2008; 11(3):318-321.

29. Allen RH, Stabler SP, Savage DG, et al. Metabolic abnormali-ties in cobalamin (vitamin B12) and folate deficiency. FASEB J.1993; 7:1344---53.

30. Qiu A, Jansen M, Sakaris A, et al. Identification of an intestinalfolate transporter and the molecular basis for hereditary folatemalabsorption. Cell. 2006; 127:917---28.

31. Bailey LB, Gregory JF. Folate metabolism and requirements. JNutr. 1999; 129:779---82.

32. Longo DL, Bunn HF. Vitamin B 12 and pernicious anemia ---- thedawn of molecular medicine. N Engl J Med. 2014; 370:773---6.

33. Hunter, R., Barnes,J., and Matthew, D. M. (1969) Effect of folic acid supplement on serum B12 levels in patients on anticonvulsants. *Lancet* 11: 666 – 671.

34. Antony AC. Vegetarianism and vitamin B-12 (cobalamin) defi-ciency. Am J Clin Nutr. 2003; 78:3---6.34.

35. Centers for Disease Control and Prevention (CDC). Neurologicimpairment in children associated with maternal dietary defi-ciency of cobalamin-Georgia, 2001. JAMA. 2003; 289-979.

36. Stein J, Stier C, Raab H, et al. Review article: the nutritional and pharmacological consequences of obesity surgery. AlimentPharmacol Ther. 2014; 40:582---609.

37. Sawaya RA, Jaffe J, Friedenberg L, et al. Vitamin, mineral, and drug absorption following bariatric surgery. Curr Drug Metab.2012;13:

38. Butler CC, Vidal-Alaball J, Cannings-John R, et al. Oral vitaminB12 versus intramuscular vitamin B12 for vitamin B12 defi-ciency: a systematic review of randomized controlled trials.Fam Pract. 2006; 23:279---85.

39. Qiu A, Jansen M, Sakaris A, et al. Identification of an intestinalfolate transporter and the molecular basis for hereditary folatemalabsorption. Cell. 2006; 127:917---28.

40. Lindenbaum J, Rosenberg IH, Wilson,PW, Stabler SP, Allen RH et al. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994; 60:2

41. Green R, Kinsella LJ et al. Editorial: Current concepts in the diagnosis of cobalamin deficiency. Neurology 1995; 45:1435.

42. Sullivan LW, Herbert V et al. Studies on the minimum daily requirement for vitamin B12. N Engl J Med 1965; 272:340.

43. Pruthi RK; Tefferi A et al. Pernicious anemia revisited. Mayo Clin Proc 1994 Feb; 69(2):144-50.

44. Allen RH, Stabler SP, Savage, Lindebaum J et al. Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J 1993; 9:1334.

45. Tefferi A; Pruthi RK et al. cobalamin deficiency. Mayo Clin Proc 1998 Feb;69(2):181-6.

46. Hoffman R, Benz EJ, Shattil SJ, et al. Megaloblastic anemias. In: Hematology: Basic principles and practice, 1995.

47. Cunha UG, Rocha FL, Peixoto JM, Motta MF, Barbosa MT et al, Vitamin B12 deficiency and dementia; Intl Psychgeriatric 1995; 7(1):85-8.

48. Eastley R, Wilcock GK, Bucks RS et al; Vitamin B12 deficiency in dementia and cognitive impairment: the effects of treatment on neuropsychological function. Int J Geriatr Psychiatry. 2000 Mar;15(3):226-33

49. Matchar DB, McCrory DC, Millington DS, Feussner JR et al. Performance of the serum cobalamin assay for diagnosis of cobalamin deficiency. Am J Med Sci 1994; 308:276.

50. Metz J; McGrath K; Bennett M, Hyland K, Bottiglieri T et al; Biochemical indices of vitamin B12 nutrition in pregnant patients with subnormal serum vitamin B12 levels. Am J Hematol 1995 Apr; 48 (4):251-5.

51. Rodríguez-de Santiago E, Ferre-Aracil C, García García-de Pare-des A., Moreira-Vicente V.F. Pernicious anemia. From past to present. Rev Clin Esp 2015 (Trabajo En Prensa, 10 Febrero 2015).

52. Pruthi RK, Tefferi A. Pernicious anemia revisited. Mayo Clin Proc.1994; 69:144---50.

53. Carmel R, Green R, Rosenblatt DS, et al. Update on cobalamin,folate, and homocysteine. Hematology Am Soc Hematol EducProgram. 2003:62---81.

54. Tietz, Fundamentals of Clinical Chemistry, Sixth edition, 2012, 489-494.

55. Bertram G, Katzung, Basic and clinical pharmacology, 12th Edition, 2012, 407-410.

56. Harpers, Illustrated Bio-chemistry, 28th Edition, 2009, 477-478.

57. Lippincot, Illustrated review of Bio-chemistry, 5th Edition, 2011, 376-378.

PROFORMA

Case No:

Name of the patient: **Age/Sex:**

Address: **Phone No:**

History Of present illness:

PAST MEDICAL HISTORY

Diabetes mellitus / Hypertension / Ischemic Heart disease / Kidney Disease / Liver Disease / Stroke/Trauma/Recent surgeries and Any other illness

DRUG HISTORY

Metformin / Oral Contraceptives / Phenytoin / Methodrexate / Omeprazole

PERSONAL HISTORY

Diet: Vegetarian / Non Vegetarian / Smoking / Alcohol

PHYSICAL EXAMINATION

Built and Nourishment: Height / Weight / Pallor / Icterus / Clubbing / Cyanosis / Edema / Lymphadenopathy

VITALS

BP / Pulse

SYSTEMIC EXAMINATION

Respiratory System

Cardiovascular System

Abdominal System

Nervous System

INVESTIGATIONS

- Complete Blood Count

1. Hemoglobin
2. Total WBC Count
3. Differential Count
4. RBC
5. Platelet Count
6. MCV
7. MCH
8. MCHC

- Peripheral Blood Smear Study
- Serum Folic Acid
- Serum Vitamin B12

GOVT. STANLEY MEDICAL COLLEGE, CHENNAI - 600001

INFORMED CONSENT

"EFFECT OF ANTIEPILEPTIC DRUG ON THE SERUM FOLATE AND VITAMIN B12 LEVEL IN EPILEPTIC PATIENTS"

Place of Study: Govt. Stanley Medical College, Chennai

I.....have been informed about the details of the study in my own language.

- I have completely understood the details of the study
- I am aware of the possible risks and benefits, while taking part in the study.
- I can understand that I can withdraw from the study at any points of time and even then, I can receive the medical treatment as usual.
- I understand that I will not get any money for taking part in the study.
- I will not object if the results of this study are getting published in any medical journal, provided my personal identity is not revealed.
- I know what I am supposed to do by taking part in this study and I assure that would extend my full cooperation for this study.

Volunteer :

Name and Address :

Signature :

Date :

Investigator :

Signature and Date :

தகவல்படிவம்

மதிப்பிற்குரிய ஐயா / அம்மையீர்,

உங்கள் விருப்பத்தின் பேரில் வலிப்பு நோயாளிகளுக்கு கொடுக்கப்படும் ஆண்டிபிலிப்டிக்கு மருந்தினால் இரத்தத்தில் வைட்டமின் B12 மற்றும் ஃபோலிக் அமிலத்தின் மாறுதல் அளவினை பற்றி கண்டறிவதற்கான ஆய்வில் பங்கேற்கும்படி அன்புடன் கேட்டுக்கொள்கிறோம். இந்த ஆய்வில் ஆரய்ச்சி நோக்கத்திற்காக தாங்கள்பரிசோதனைக்கு உட்படுத்தப்படுவீர்கள். தகுந்த சிகிச்சை தங்களுக்கு தொடங்கப்படும். தங்களுக்கு இந்த ஆய்வில் பங்கேற்க விருப்பம் இருந்தால் தாங்கள் அருள்கூர்ந்து ஒப்புதல் படிவத்தைப் படித்துப்பார்த்துக் கையொப்பம் இடும்படிக் கேட்டுக்கொள்கிறேன்.

S Kavitha
11/12/17

ஆராய்ச்சிநிலையம் அரசுமருத்துவமனை சென்னை

பங்குபெறுபவரின்பெயர்

பங்குபெறுபவரின்வயது

பங்குபெறுபவர் ( ) இதனைக்குறிக்கவும்

மேலேகுறிப்பிடப்பட்டுள்ள ஆய்வின்விவரங்கள்எனக்குவிளக்கப்பட்டது.

என்னுடையஐயங்களைக்கேட்கவும்.

அதற்கானதகுந்தவிளக்கங்களைப்பெறவும்வாய்ப்புஅளிக்கப்பட்டது நானிவ்வாய்வில்தன்னிச்சையாகத்தான்

பங்கேற்கிறேன் எந்தகாரணத்தினாலோஎந்தகட்டத்திலும்எந்தச்சட்டசிக்கலுக்கும்உட்படாமலோதான

இவ்வாய்வில் இருந்துவிலகிக் கொள்ளலாம்என்றும்அறிந்துகொண்டேன்

இந்தஆய்வுசம்பந்தமாகவோ இதைச்சார்ந்தவேறுமாஆய்வுமேற்கொள்ளும்போதும் இந்தஆய்வில்பங்கு

பெறுமருத்துவர்என்னுடையமருத்துவஅறிக்கைகளைபார்ப்பதற்குஎனதுமறுமதிதேவையில்லையெனஅறிந்து

கொள்கிறேன் நான ஆய்வில் இருந்துவிலகிகொண்டாலும்இதுபொருந்தும்எனஅறிகிறேன்

இந்தஆய்வுமூலம்கிடைக்குமருத்தகவல்களையும்பரிசோதனைமுடிவுகளையும்மற்றும்சிகிச்சைதொடர்பான

தகவல்களையும்மருத்துவர்மேற்கொள்ளும்ஆய்வில்பயன்படுத்திக்கொள்ளவும்அதைப்பிரசுரிக்கவும்என

முழுமனதுடன்சம்மதிக்கிறேன

இந்தஆய்வில்பங்குகொள்ளஒப்புக்கொள்கிறேன் எனக்குதரப்பட்டஅறிவுரைபடிநடந்துகொள்வ

துடன்இந்தஆய்வைமேற்கொள்ளும்மருத்துவக்குழுவினருக்கு எவ்வகையிலும்இடையூறுசெய்யமாட்டேன்என்றும்உறுதிஅளிக்கின்றேன்

என்உடல்நலம்பாதிக்கப்பட்டாலோஅல்லதுஎதிர்பாராதவழக்கத்திற்குமாறானநோய்க்குறிதென்பட்டாலோ

உடனேஎனதுமருத்துவக்குழுத்தலைவரைஅணுகுவேன்என்றும்உறுதிஅளிக்கிறேன்

பங்குபெறுபவரின்கையொப்பம் _____ இடம் _____ தேதி _____

கட்டைவிரல்ரேகை

பங்குபெறுபவரின் பெயர்மற்றும்விலாசம் _____

_____

ஆய்வாளரின்கையொப்பம் _____ இடம் _____ தேதி _____

ஆய்வாளரின்பெயர் மரு எஸ்.கவிதா